OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press63610.17650/1818-8346-2006-0-1-2-9-15BIOLOGY OF HEMATOLOGIC MALIGNANCIESБИОЛОГИЯ ГЕМОБЛАСТОЗОВMultidrug resistance markers in acute myeloid leukemiasМаркеры множественной лекарственной устойчивости при острых миелоидных лейкозахZakharovO. D.ЗахаровО. Д.
Russian Federation

Moscow

Москва

RybalkinaYe. Yu.РыбалкинаЕ. Ю.
Russian Federation

Moscow

Москва

VolkovaM. A.ВолковаМ. А.
Russian Federation

Moscow

Москва

StavrovskayaA. A.СтавровскаяА. А.
Russian Federation

Moscow

Москва

N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical SciencesРоссийский онкологический научный центр им. Н.Н. Блохина РАМНN.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical SciencesГУ РОНЦ им. Н.Н. Блохина РАМН230520061-291522112022221120222006https://oncohematology.abvpress.ru/ongm/article/view/636

Multidrug resistance (MDR) is the cell resistance to a number of drugs. Proteins from the ABC-transporter family are the most studied factors of the MDR phenomenon. According to the literature Pgp, MRP1, BCRP, and LRP are proteins involved in the development of the MDR. The authors detected the expression of these proteins in untreated patients with acute myeloid leukemia (other than M3). Expression of these proteins was observed in 64.3%, 46.4%, 64.3%, and 42.9% of patients, respectively. In all non-responders blast cells expressed more than one marker of MDR. Expression of 3 and 4 markers was found in 80% of non-responders while in responders 1—2 markers were expressed in 83%.

.

acute myeloid leukemiaMDRPgpMRP1BCRPLRP71. Савченко В.Г., Паровичникова Е.Н. Лечение острых лейкозов. М., 2004.Савченко В.Г., Паровичникова Е.Н. Лечение острых лейкозов. М., 2004.72. Ставровская А.А. Резистентность больных гемобластозами к лекарственной терапии. В кн.: Клиническая онкогематология. Под ред. М.А. Волковой. М., Медицина; 2001.Ставровская А.А. Резистентность больных гемобластозами к лекарственной терапии. В кн.: Клиническая онкогематология. Под ред. М.А. Волковой. М., Медицина; 2001.73. Gregory D.L., Tito F., Susan E.B. The role of ABC transporters in clinical practice. The Oncologist 2003; 8(5):411—24.Gregory D.L., Tito F., Susan E.B. The role of ABC transporters in clinical practice. The Oncologist 2003; 8(5):411—24.74. Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11(7):1156—66.Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11(7):1156—66.75. Riordan J.R., Ling V. Purification of Pglycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 1979;254(24):12701—5.Riordan J.R., Ling V. Purification of Pglycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. J Biol Chem 1979;254(24):12701—5.76. Guerci A., Merlin J.L., Missoum N. et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995;85: 2147—53.Guerci A., Merlin J.L., Missoum N. et al. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995;85: 2147—53.77. van der Kolk D.M., de Vries E.G., van Putten W.J. et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 2000;6:3205—14.van der Kolk D.M., de Vries E.G., van Putten W.J. et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 2000;6:3205—14.78. Marie J.P., Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol 1999;457:1—9.Marie J.P., Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol 1999;457:1—9.79. Leith C.P., Kopecky K.J., I-Ming Chen et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group Study. Blood 1999;94(3): 1086—99.Leith C.P., Kopecky K.J., I-Ming Chen et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group Study. Blood 1999;94(3): 1086—99.80. Benderra Z., Faussat A.M., Sayadaye L. et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005;11:7764—72.Benderra Z., Faussat A.M., Sayadaye L. et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005;11:7764—72.81. van Stijn A., van der Pol M.A., Kok A. et al. Differences between the CD34+ and CD34blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 2003;88(5):497—508.van Stijn A., van der Pol M.A., Kok A. et al. Differences between the CD34+ and CD34blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica 2003;88(5):497—508.82. Legrand O., Zompi S., Perrot J.Y. et al. P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups. Haematologica 2004;89(1):34—41.Legrand O., Zompi S., Perrot J.Y. et al. P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups. Haematologica 2004;89(1):34—41.83. Damiani D., Tiribelli M., Calistri E. et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006;91:825—8.Damiani D., Tiribelli M., Calistri E. et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006;91:825—8.84. Hunter H.M., Pallis M., Seedhouse C.H. et al. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors. Br J Hemat 2004;127(1):26—33.Hunter H.M., Pallis M., Seedhouse C.H. et al. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors. Br J Hemat 2004;127(1):26—33.85. Cole S.P., Bhardwaj G., Gerlach J.H. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258(5088):1650—4.Cole S.P., Bhardwaj G., Gerlach J.H. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258(5088):1650—4.86. Zhou D.C., Zittoun R., Marie J.P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia. 1995;9(10):1661—6.Zhou D.C., Zittoun R., Marie J.P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia. 1995;9(10):1661—6.87. Filipits M., Stranzl T., Pohl G. et al. MRP expression in acute myeloid leukemia. An update. Adv Exp Med Biol 1999;457:141—50.Filipits M., Stranzl T., Pohl G. et al. MRP expression in acute myeloid leukemia. An update. Adv Exp Med Biol 1999;457:141—50.88. Schaich M., Soucek S., Thiede Ch. et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Hemat 2005;128(3):324—32.Schaich M., Soucek S., Thiede Ch. et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Hemat 2005;128(3):324—32.89. Kuss B.J., Deeley R.G., Cole S.P. et al. The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Leuk Lymphoma 1996;20(5—6):357—64.Kuss B.J., Deeley R.G., Cole S.P. et al. The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Leuk Lymphoma 1996;20(5—6):357—64.90. Doyle L.A., Yang W., Abruzzo L.V. et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci 1998;95:15665—70.Doyle L.A., Yang W., Abruzzo L.V. et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci 1998;95:15665—70.91. Benderra Z., Faussat A.-M., Sayada L. et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004;10:7896—902.Benderra Z., Faussat A.-M., Sayada L. et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004;10:7896—902.92. Abbott B.L., Colapietro A.-M., Barnes Y. et al. Low levels of ABCG2 expression in adult AML blast samples. Blood 2002;100(13):4594—601.Abbott B.L., Colapietro A.-M., Barnes Y. et al. Low levels of ABCG2 expression in adult AML blast samples. Blood 2002;100(13):4594—601.93. List A.F., Spier C.S., Grogan T.M. et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996;87(6):2464—9.List A.F., Spier C.S., Grogan T.M. et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996;87(6):2464—9.94. Pirker R., Pohl G., Stranzl T. et al. The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia. Adv Exp Med Biol 1999;457:133—9.Pirker R., Pohl G., Stranzl T. et al. The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia. Adv Exp Med Biol 1999;457:133—9.95. Filipits M., Pohl G., Stranzl Th. et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998;91(5): 1508—13.Filipits M., Pohl G., Stranzl Th. et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998;91(5): 1508—13.96. Huh H.J., Park C.J., Jang S. et al. Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 2006;21(2):253—8.Huh H.J., Park C.J., Jang S. et al. Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 2006;21(2):253—8.